Avanos Medical, Inc. (NYSE:AVNS - Free Report) - Stock analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for shares of Avanos Medical in a research note issued to investors on Monday, April 28th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.26 for the quarter, down from their prior estimate of $0.29. The consensus estimate for Avanos Medical's current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical's Q4 2025 earnings at $0.41 EPS, FY2025 earnings at $1.17 EPS, Q1 2026 earnings at $0.24 EPS, Q2 2026 earnings at $0.27 EPS, Q3 2026 earnings at $0.37 EPS, Q4 2026 earnings at $0.45 EPS, FY2026 earnings at $1.33 EPS and Q1 2027 earnings at $0.34 EPS.
Avanos Medical (NYSE:AVNS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, topping analysts' consensus estimates of $0.40 by $0.03. The firm had revenue of $179.60 million during the quarter, compared to analyst estimates of $177.23 million. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%.
Separately, StockNews.com raised Avanos Medical from a "hold" rating to a "buy" rating in a research report on Wednesday, March 19th.
Get Our Latest Stock Analysis on AVNS
Avanos Medical Stock Down 0.4 %
Shares of NYSE:AVNS traded down $0.05 during midday trading on Tuesday, reaching $12.28. The company had a trading volume of 362,319 shares, compared to its average volume of 339,227. The business's 50 day moving average price is $13.69 and its 200 day moving average price is $16.34. Avanos Medical has a 1-year low of $11.84 and a 1-year high of $25.36. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12. The stock has a market cap of $564.92 million, a PE ratio of 36.12 and a beta of 1.13.
Institutional Investors Weigh In On Avanos Medical
A number of hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP bought a new stake in Avanos Medical during the 4th quarter valued at $64,000. State of Wyoming raised its stake in shares of Avanos Medical by 132.0% during the 4th quarter. State of Wyoming now owns 5,137 shares of the company's stock valued at $82,000 after purchasing an additional 2,923 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Avanos Medical by 493.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company's stock worth $129,000 after purchasing an additional 6,714 shares in the last quarter. Heritage Family Offices LLP bought a new position in Avanos Medical in the 1st quarter worth about $146,000. Finally, EP Wealth Advisors LLC grew its holdings in Avanos Medical by 14.6% during the 4th quarter. EP Wealth Advisors LLC now owns 10,108 shares of the company's stock valued at $161,000 after buying an additional 1,289 shares in the last quarter. Institutional investors own 95.17% of the company's stock.
Insiders Place Their Bets
In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of Avanos Medical stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $15.25, for a total transaction of $106,750.00. Following the completion of the transaction, the senior vice president now owns 82,047 shares in the company, valued at approximately $1,251,216.75. The trade was a 7.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.64% of the company's stock.
Avanos Medical Company Profile
(
Get Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Read More
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
